Cara Therapeutics Inc (NASDAQ:CARA) saw some unusual options trading activity on Thursday. Stock investors bought 1,753 call options on the stock. This represents an increase of approximately 808% compared to the typical daily volume of 193 call options.

Shares of Cara Therapeutics (NASDAQ CARA) opened at $13.54 on Friday. Cara Therapeutics has a twelve month low of $8.62 and a twelve month high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.03). During the same period in the previous year, the company earned ($0.42) earnings per share. sell-side analysts predict that Cara Therapeutics will post -1.84 EPS for the current year.

In other news, CEO Derek T. Chalmers sold 16,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the sale, the chief executive officer now owns 1,066,292 shares in the company, valued at approximately $13,499,256.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the business. Legal & General Group Plc raised its holdings in Cara Therapeutics by 10.4% during the 2nd quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 678 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of Cara Therapeutics by 15.4% in the 2nd quarter. Voya Investment Management LLC now owns 12,316 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 1,646 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Cara Therapeutics by 18.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,280 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 3,353 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Cara Therapeutics by 25.0% in the 3rd quarter. Janney Montgomery Scott LLC now owns 21,365 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 4,275 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Cara Therapeutics by 16.7% in the 2nd quarter. Rhumbline Advisers now owns 30,537 shares of the biopharmaceutical company’s stock valued at $470,000 after acquiring an additional 4,375 shares during the last quarter. 58.80% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on CARA. CIBC cut their price target on Cara Therapeutics from $26.00 to $24.00 in a report on Tuesday, November 7th. Canaccord Genuity set a $25.00 price target on Cara Therapeutics and gave the company a “buy” rating in a report on Monday, November 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Cara Therapeutics in a report on Wednesday, October 4th. Zacks Investment Research raised Cara Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, August 30th. Finally, BidaskClub raised Cara Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $25.17.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/10/cara-therapeutics-target-of-unusually-large-options-trading-cara.html.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Ratings for Cara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.